Apotex at the end of February started its national launch of its Lapelga (pegfilgrastim) biosimilar version of Amgen’s Neulasta reference brand. The roll-out of the 6mg/0.6ml syringes through the Canadian group’s Apobiologix division comes almost a year after Health Canada approved the biosimilar neutropenia treatment in early April 2018, just under one year after receiving Apobiologix’ filing.
Apotex Rolls Out Pegfilgrastim A Year After Canadian Approval
Apotex is rolling out its Lapelga pegfilgrastim biosimilar across Canada, almost a year after securing marketing authorization. But Mylan is seeking local reimbursement for its Fulphila alternative.
More from Biosimilars
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.